Central Precocious Puberty (CPP) Treatment Market Report 2024

This Central Precocious Puberty (CPP) Treatment market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The central precocious puberty (CPP) treatment market size has grown strongly in recent years. It will grow from $1.56 billion in 2023 to $1.69 billion in 2024 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to rise in demand for disease-specific treatments, rise in awareness, rise in the pediatric population, availability of comprehensive treatment guidelines, and patient support programs.

The central precocious puberty (CPP) treatment market size is expected to see strong growth in the next few years. It will grow to $2.34 billion in 2028 at a compound annual growth rate (CAGR) of 8.4%. The growth during the forecast period can be attributed to awareness campaigns by non-governmental organizations, the expansion of health insurance coverage, improved access to healthcare services, a heightened focus on child health, and an increase in clinical trials. Major trends expected in this period include the adoption of hormone therapies and biosimilar drugs, the use of telemedicine, advancements in genomic research, and greater digitalization in healthcare.

The rising incidence of hormonal disorders is anticipated to drive the expansion of the central precocious puberty (CPP) treatment market in the coming years. Hormonal disorders encompass various medical conditions resulting from imbalances in hormone levels within the body. This increase in hormonal disorders is a complex issue influenced by factors such as modern lifestyle choices, environmental exposures, and genetic or epigenetic influences. CPP treatment primarily focuses on managing the early onset of puberty linked to hormonal imbalances, typically using gonadotropin-releasing hormone (GnRH) analogs to suppress the hormonal signals that initiate puberty. For example, a report by Wiley, a US-based publisher, indicated that the prevalence of endocrine disorders had risen to 18% after 6 months, with females being more commonly affected. As a result, the growing prevalence of hormonal disorders is fueling the growth of the CPP treatment market.

Leading companies in the CPP treatment market are developing innovative parenteral depot medications to improve treatment outcomes and patient adherence. These medications offer sustained-release hormone suppression, which helps delay premature sexual development and manage symptoms more effectively over a longer period. For instance, in November 2022, Cipla Limited, an India-based pharmaceutical company, introduced Leuprolide Acetate Injection Depot 22.5mg. This product is used for treating advanced prostate cancer and CPP. It is administered as a single dose every three months and comes in the form of lyophilized microspheres in a vial, accompanied by a prefilled syringe and MIXJECT transfer device for ease of administration.

In December 2023, Zydus Lifesciences Ltd., an India-based pharmaceutical firm, entered into a partnership with Daewoong Pharmaceutical. This collaboration aims to combine Zydus' clinical development and commercialization expertise with Daewoong's proprietary technology and manufacturing capabilities to advance the development and availability of leuprolide acetate for depot suspension in the U.S. market. This partnership is intended to improve patient access to this crucial treatment. Daewoong Pharmaceutical Co. Ltd., based in South Korea, specializes in the research, development, and production of pharmaceutical products, including leuprolide acetate for treating CPP.

Major companies operating in the central precocious puberty (CPP) treatment market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Sun Pharmaceutical Industries Ltd., Ipsen S.A., Varian Medical Systems Inc., Dr Reddy's Laboratories Limited, Endo Pharmaceuticals Inc., Livzon Pharmaceutical Group Co. Ltd., Daewoong Pharmaceutical Co.Ltd, Bachem Holding AG, Ferring Pharmaceuticals, Tolmar Pharmaceuticals Inc., Arbor Pharmaceuticals, Debiopharm Group, Beijing Biote Pharmaceutical Ltd, GP Pharm S.A.

North America was the largest region in the central precocious puberty (CPP) treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the central precocious puberty (CPP) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the central precocious puberty (CPP) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Central precocious puberty (CPP) treatment involves medical interventions designed to manage and delay the early onset of puberty caused by the premature activation of the hypothalamic-pituitary-gonadal (HPG) axis. CPP is characterized by the appearance of secondary sexual characteristics before age 8 in girls and before age 9 in boys. The primary treatment method is the use of gonadotropin-releasing hormone (GnRH) agonists, which suppress the early release of sex hormones and slow or stop the progression of puberty.

The central precocious puberty (CPP) treatment market primarily includes medications and surgery. Medications are used to delay the onset of puberty, while surgeries may be considered in certain cases. Diagnosis is performed using blood tests, magnetic resonance imaging (MRI), computed tomography (CT) scans, and X-rays. The treatments are available for both girls and boys, and the main end-users include hospitals, specialty clinics, homecare settings, and other healthcare facilities.

The central precocious puberty (CPP) treatment market research report is one of a series of new reports that provides central precocious puberty (CPP) treatment market statistics, including the central precocious puberty (CPP) treatment industry global market size, regional shares, competitors with central precocious puberty (CPP) treatment market share, detailed central precocious puberty (CPP) treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the central precocious puberty (CPP) treatment industry. These central precocious puberty (CPP) treatment market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The central precocious puberty (CPP) treatment market consists of revenues earned by entities by providing services such as endocrinology consultations, regular hormone assessments, and growth monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The central precocious puberty (CPP) treatment market also includes sales of Leuprolide acetate, Triptorelin, Histrelin, and Goserelin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.